



Weight Change–Adjusted Effects of Gastric Bypass Surgery on Glucose Metabolism: 2- and 10-Year Results From the Swedish Obese Subjects (SOS) Study

Kajsa Sjöholm,¹ Elisabeth Sjöström,¹
Lena M.S. Carlsson,¹ and
Markku Peltonen²

Diabetes Care 2016;39:625–631 | DOI: 10.2337/dc15-1407

OBJECTIVE

It has been suggested that weight change–independent effects on fasting insulin and glucose levels are present after gastric bypass (GBP) but not after banding and vertical banded gastroplasty (VBG). We therefore evaluated weight change–adjusted effects of GBP, compared with restrictive surgical procedures, on long-term changes in fasting levels of glucose, insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) in the Swedish Obese Subjects (SOS) study.

RESEARCH DESIGN AND METHODS

Participants who completed the 2-year ($n = 1,762$) and/or the 10-year ($n = 1,216$) follow-up were divided into three weight change classes (weight loss $>30\%$, $20\text{--}30\%$, or $\leq 20\%$), and by surgical method (banding, VBG, or GBP). Glucose, insulin, and HOMA-IR changes were analyzed in relation to weight change over 2 and 10 years. Analyses were performed in the full cohort and also in subgroups based on baseline glucose status.

RESULTS

Within weight change classes, reductions in glucose, insulin, and HOMA-IR were similar in the three surgery groups both at 2 and at 10 years. Reductions in glucose, insulin, and HOMA-IR increased with increasing weight loss, and changes were typically related to weight change within each surgery group. Moreover, the association between weight change and change in glucose, insulin, or HOMA-IR did not differ between the surgery groups at 2 and 10 years. When patients were subdivided also by baseline glucose status, similar relationships between weight changes and changes in glucose, insulin, and HOMA-IR were observed.

CONCLUSIONS

Even though weight loss–independent effects are important for short-term diabetes remission, our results suggest that degree of weight loss is more important for long-term reductions in fasting insulin and glucose than choice of bariatric surgery procedure.

¹Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

²Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland

Corresponding author: Kajsa Sjöholm, kajsa.sjoholm@medic.gu.se.

Received 29 June 2015 and accepted 25 October 2015.

Clinical trial reg. no. NCT01479452, clinicaltrials.gov.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1407/-/DC1>.

K.S. and E.S. contributed equally and should both be considered first authors.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Type 2 diabetes is related to obesity and characterized by elevated fasting plasma glucose concentrations (1,2) due to insulin resistance, with high hepatic glucose output and decreased glucose uptake in peripheral tissues (3). Type 2 diabetes is a chronic condition, but over the last 15 years it has been shown repeatedly (4–14) that bariatric surgery is associated with a high diabetes remission rate, and a systematic review concluded that 78% of patients with diabetes achieved resolution in the first 2 years after surgery (rev. in 6). Long-term results (10–15 years) also demonstrate high remission rates as well as reduced incidence of diabetes complications in surgery patients (15,16).

Gastric bypass (GBP) is associated with more pronounced effects on glucose homeostasis short term compared with gastric banding and other restrictive procedures (6). It has been suggested that early remission of diabetes after GBP is caused by surgery-specific, weight loss-independent effects on glucose homeostasis (17,18). Changes in the postprandial secretory pattern of incretins, such as glucagon-like peptide 1, are generally suggested as the major component of this effect, although alterations in dietary habits, gastric emptying, bile acids, and/or microbiota have also been put forward as possible mechanisms that could explain this phenomenon (19). Indeed, remission of type 2 diabetes has been reported within days to weeks after GBP surgery, before substantial weight reduction has occurred (20,21).

The changes in the incretin secretion patterns occur in the first few months after surgery, but weight loss change persists over a long time. In most studies, results suggest that GBP is more effective for achieving major weight reduction and higher rates of diabetes remission compared with restrictive procedures (5,8,10). However, adjustments for degree of weight loss have seldom been performed in these analyses, and some reports indicate that magnitude of weight loss is the major determinant of whether obese patients with diabetes achieve remission both up to and after 2 years (6,12,22–24). Furthermore, several recent studies challenge the importance of the incretin effect, implying that caloric restriction could instead be a main explanatory factor (25–29).

As part of the Swedish Obese Subjects (SOS) study, we have previously published several reports on the long-term (10–20 years) effects of bariatric surgery (4,15,30–34). Similar to the reports referenced above, our data suggest that weight loss and risk factor changes are most prominent for patients treated with GBP (4). However, whether weight loss-independent effects on fasting insulin and glucose levels are present after GBP but not after banding and VBG procedures has not been analyzed. Therefore, in the current report we evaluate weight loss-independent effects of GBP compared with restrictive surgical procedures on changes in fasting glucose and insulin levels over 2 and 10 years of follow-up.

RESEARCH DESIGN AND METHODS

General Study Design

The nonrandomized prospective SOS intervention trial enrolled 4,047 obese subjects (34,35). In brief, 6,905 subjects participated in an initial matching examination. In this examination, 5,335 individuals were found to be eligible. (See below.) Among eligible patients, 2,010 choosing surgery formed the surgery group and a contemporaneously matched control group ($n = 2,037$) was created using 18 matching variables. The two study groups had identical inclusion and exclusion criteria. The inclusion criteria were age 37–60 years and BMI ≥ 34 kg/m² for men and ≥ 38 kg/m² for women before or at the matching examination. The exclusion criteria were few and were aimed at obtaining operable subjects. Baseline examinations of subjects in both groups took place 4 weeks before surgery. The intervention began on the day of surgery for subjects in the surgery group and for their matched control subjects. Patients were then re-examined after 0.5, 1, 2, 3, 4, 6, 8, 10, 15, and 20 years (34). Seven regional ethics review boards approved the study protocol, and informed consent was obtained from all subjects. Of the 2,010 subjects in the surgery group, 376 underwent nonadjustable or adjustable gastric banding, 1,369 underwent vertical banded gastroplasty (VBG), and 265 underwent GBP.

Report Population, Examinations, and Data Analysis

For the current report, only surgery patients were included. We used biochemical examinations, body weights, and other anthropometric measurements at baseline,

2 years, and 10 years. Fasting blood samples were obtained in the morning after an overnight fast. Fasting glucose concentrations were measured in venous whole blood from 1987 to 2009. After 2009, venous plasma glucose was measured and converted to blood glucose (conversion factor 1.12, $R^2 = 98.9$). Biochemical measurements were undertaken at the Central Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. The laboratory is accredited according to International Organization for Standardization/International Electrotechnical Commission (ISO/IEC) 15189:2007 standards.

Type 2 diabetes was defined as fasting blood glucose ≥ 6.1 mmol/L (corresponding to fasting plasma glucose ≥ 7.0 mmol/L) and/or self-reported therapy with glucose-lowering medications at baseline. Impaired fasting glucose was defined as fasting blood glucose ≥ 5.0 to < 6.1 mmol/L (fasting plasma glucose ≥ 5.6 to < 7.0 mmol/L) (2). The study was initiated before repeated measurements were routinely used for the diagnosis of type 2 diabetes; therefore, single fasting glucose determinations were used. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as fasting plasma insulin (pmol/L) \times fasting plasma glucose (mmol/L)/135.

We analyzed glucose and insulin changes over 2 and 10 years in relation to weight change.

Patients who had been converted from the original to another surgical method between baseline and 2 years or baseline and 10 years were not included in the calculations ($n = 67$ and $n = 307$ patients were excluded from 2- and 10-year analyses, respectively).

Patients with missing values for body weight, glucose, and insulin at baseline or at the follow-up time points were excluded (a total of 29 and 30 patients for 2- and 10-year analyses, respectively). For the main analysis, patients were divided into three relative weight change classes (designated by percent weight change over 2 or 10 years: weight loss $> 30\%$, between 20 and 30%, or $\leq 20\%$) and by surgical method (banding, VBG, or GBP). For the subgroup analysis, patients were also subdivided by baseline glucose status; one group consisted of patients with normal fasting glucose at baseline, and one group consisted of patients with impaired fasting glucose or type 2 diabetes at baseline. The patients with impaired

fasting glucose and patients with type 2 diabetes were pooled to obtain subgroups large enough to allow subgrouping by weight change class and surgery method.

Statistical Methods

Mean values, with SDs, and percentages were used to describe the baseline characteristics and changes over 2 and 10 years in different surgery groups. Changes in fasting glucose, insulin, and HOMA-IR were analyzed by ANCOVA in the three surgery groups, adjusting for baseline levels of respective variable, degree of weight change, sex, and age. Statistical analyses were performed with Stata software (version 12.1; College Station, TX). All *P* values are two sided, and *P* < 0.05 was considered statistically significant.

RESULTS

Baseline Characteristics and 2-Year and 10-Year Weight Changes

Table 1 shows baseline characteristics and weight change by weight change class and type of surgery for all patients who completed the 2- and 10-year follow-up, respectively. Within given weight change classes, baseline glucose, insulin, and HOMA-IR did not differ between the three surgery groups. Supplementary Table 1 shows the baseline data and 2-year and 10-year weight changes separately for patients with normal fasting glucose and with impaired fasting glucose/type 2 diabetes. At the 2-year follow-up, ~20% of the banding and VBG patients achieved >30% weight loss compared with 59% in the GBP group. After 10 years, the percentages achieving >30% weight loss were 25% in the GBP group compared with 14% and 8% in the banding and VBG groups, respectively. The fractions of patients who completed the 2- and 10-year follow-up were 88% and 60%, respectively.

Changes in Glucose, Insulin, and HOMA-IR Over 2 and 10 Years

Within given weight change classes, fasting levels of glucose (Fig. 1A), fasting levels of insulin (Fig. 1B), and HOMA-IR (Fig. 1C) changes were similar after GBP, banding, and VBG both at 2 and at 10 years. In principle, the same was true within the normal fasting glucose and impaired fasting glucose/type 2 diabetes groups, although all changes were larger in the latter subgroup (Supplementary Figs. 1–3).

Table 1—Baseline characteristics and weight changes in obese SOS surgery patients by 2- and 10-year weight change and type of surgery

| | >30% weight change | | | 20–30% weight change | | | ≤20% weight change | | |
|------------------------|--------------------|-------------|--------------|----------------------|-------------|-------------|--------------------|-------------|-------------|
| | Banding | VBG | GBP | Banding | VBG | GBP | Banding | VBG | GBP |
| 2-year data | | | | | | | | | |
| Completers, N (%)* | 71 (21) | 258 (22) | 140 (59) | 90 (27) | 419 (35) | 68 (29) | 170 (51) | 516 (43) | 30 (13) |
| Baseline data | | | | | | | | | |
| Males, % | 27 | 31 | 21 | 27 | 26 | 28 | 36 | 31 | 40 |
| Age, years | 47 ± 6 | 47 ± 6 | 46 ± 6 | 48 ± 6 | 47 ± 6 | 48 ± 6 | 48 ± 6 | 48 ± 6 | 48 ± 6 |
| BMI, kg/m ² | 43.0 ± 4.2 | 43.7 ± 4.7 | 44.7 ± 5.4 | 41.6 ± 4.0 | 42.3 ± 3.9 | 42.7 ± 4.1 | 40.9 ± 4.3 | 41.4 ± 4.1 | 41.7 ± 4.0 |
| Glucose, mmol/L | 4.9 ± 1.5 | 5.0 ± 1.7 | 5.2 ± 1.8 | 4.7 ± 1.2 | 4.9 ± 1.9 | 5.8 ± 2.6 | 5.3 ± 2.0 | 5.3 ± 2.1 | 5.6 ± 2.7 |
| Insulin, pmol/L | 129 ± 79 | 127 ± 67 | 127 ± 69 | 116 ± 62 | 128 ± 72 | 116 ± 49 | 131 ± 69 | 130 ± 91 | 119 ± 56 |
| HOMA-IR | 5.0 ± 3.8 | 4.9 ± 3.5 | 5.0 ± 3.6 | 4.2 ± 2.8 | 4.9 ± 4.4 | 5.2 ± 3.6 | 5.6 ± 5.0 | 5.4 ± 5.1 | 4.9 ± 3.0 |
| 2-year changes | | | | | | | | | |
| Body weight change, kg | −46.9 ± 11.2 | −44.7 ± 9.2 | −48.2 ± 12.8 | −29.7 ± 5.5 | −29.4 ± 5.0 | −31.4 ± 5.2 | −14.6 ± 7.0 | −16.2 ± 6.2 | −19.3 ± 5.0 |
| Body weight change, % | −38.0 ± 6.2 | −35.8 ± 4.9 | −37.7 ± 5.7 | −24.9 ± 3.0 | −24.7 ± 2.9 | −25.8 ± 3.0 | −12.1 ± 5.5 | −13.7 ± 5.0 | −16.2 ± 3.2 |
| 10-year data | | | | | | | | | |
| Completers, N (%)* | 28 (14) | 65 (8) | 42 (25) | 32 (16) | 197 (23) | 68 (40) | 144 (71) | 579 (69) | 61 (36) |
| Baseline data | | | | | | | | | |
| Males, % | 25 | 26 | 14 | 19 | 31 | 22 | 38 | 29 | 43 |
| Age, years | 47 ± 6 | 47 ± 6 | 47 ± 6 | 46 ± 6 | 47 ± 6 | 47 ± 6 | 48 ± 6 | 48 ± 6 | 48 ± 6 |
| BMI, kg/m ² | 44.0 ± 4.8 | 42.9 ± 4.2 | 43.8 ± 5.7 | 42.3 ± 3.3 | 42.3 ± 3.9 | 43.5 ± 4.4 | 40.6 ± 3.9 | 41.8 ± 4.1 | 41.9 ± 4.0 |
| Glucose, mmol/L | 5.2 ± 1.6 | 5.1 ± 2.0 | 4.9 ± 1.7 | 5.2 ± 1.7 | 5.3 ± 2.2 | 5.5 ± 2.2 | 4.9 ± 1.4 | 5.1 ± 2.0 | 5.4 ± 2.4 |
| Insulin, pmol/L | 133 ± 68 | 142 ± 187 | 108 ± 52 | 142 ± 75 | 128 ± 70 | 132 ± 65 | 121 ± 65 | 123 ± 64 | 115 ± 48 |
| HOMA-IR | 5.5 ± 4.1 | 5.8 ± 11.0 | 4.3 ± 3.8 | 5.6 ± 3.5 | 5.3 ± 4.8 | 5.6 ± 4.4 | 4.7 ± 3.7 | 4.8 ± 3.7 | 4.6 ± 2.6 |
| 10-year changes | | | | | | | | | |
| Body weight change, kg | −50.4 ± 10.8 | −43.8 ± 8.0 | −46.1 ± 13.1 | −29.4 ± 4.6 | −29.5 ± 5.1 | −30.1 ± 4.5 | −7.8 ± 9.9 | −12.0 ± 8.4 | −16.2 ± 7.4 |
| Body weight change, % | −39.7 ± 5.9 | −36.0 ± 4.5 | −37.6 ± 5.6 | −24.4 ± 3.0 | −24.3 ± 2.8 | −24.5 ± 2.6 | −6.6 ± 8.4 | −10.1 ± 6.9 | −13.1 ± 5.4 |

Data are presented as mean ± SD. *Proportion within each surgery group achieving the different degree of weight change.




Figure 1—Two-year and 10-year changes in fasting blood glucose (A), fasting serum insulin (B), and HOMA-IR (C) by relative weight change class and type of bariatric surgery in all patients. Left panels: 2-year changes. Right panels: 10-year changes.

Figure 1A–C suggests that reductions in glucose, insulin, and HOMA-IR increase with increasing weight loss. Moreover,

the slopes of the regression analyses revealed that weight changes at 2 and 10 years were, for all performed analyses,

associated with changes in glucose, insulin, and HOMA-IR within each of the surgery groups (Table 2). Furthermore, when we specifically tested whether the association between weight change (%) and change in glucose, insulin, and HOMA-IR differed between the three surgery groups, we found that this was not the case. The regression slope for GBP was similar to the banding and VBG regression slopes both at 2 and at 10 years (Table 2) (P values for test of equal slopes all nonsignificant).

We also performed a regression analysis in the normal fasting glucose and impaired fasting glucose/type 2 diabetes subgroups. In Supplementary Table 2, slopes are shown separately for patients with normal fasting glucose and those with impaired fasting glucose/type 2 diabetes. For glucose, we were unable to detect a difference between GBP versus banding and VBG slopes in either group both at the 2-year and at the 10-year follow-up (Supplementary Table 2) (P values for test of equal slopes all nonsignificant). The above was true also for insulin and HOMA-IR in the impaired fasting glucose/type 2 diabetes group (Supplementary Table 2). In contrast, in the normal fasting glucose group there were significant differences both at 2 years (insulin, $P = 0.025$, and HOMA-IR, $P = 0.031$) and at 10 years (insulin, $P = 0.045$) (Supplementary Table 2).

CONCLUSIONS

This report suggests that within a given weight change class, the changes in fasting insulin and HOMA-IR over 2 and 10 years are similar with banding, VBG, and GBP. In addition, changes in fasting glucose within each weight change class were either similar or even smaller after GBP than after banding and VBG. The glucose and insulin reductions increased with increasing weight loss and were larger in impaired fasting glucose/type 2 diabetes than in patients with normal fasting glucose.

A large number of short-term reports (0.1–4 years) suggest that GBP is more efficient than banding in improving glucose and insulin levels and that GBP causes higher rates of type 2 diabetes remission (reviewed in 6,8,10). Most reports on weight loss-independent effects of GBP on glucose and insulin levels are based on observations a few weeks postoperatively before major

Table 2—Regression slopes (b) for changes in glucose, insulin, and HOMA-IR by 5% weight change in the three surgical groups (banding, VBG, and GBP)

| Variable change/year | Banding b-coefficient (95% CI) | VBG b-coefficient (95% CI) | GBP b-coefficient (95% CI) | P for test of equal slopes |
|-------------------------|-----------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Glucose | | | | |
| 2-year | 0.10 (0.06–0.15) | 0.13 (0.10–0.16) | 0.09 (0.05–0.14) | 0.139 |
| 10-year | 0.17 (0.12–0.22) | 0.19 (0.14–0.24) | 0.21 (0.08–0.33) | 0.787 |
| Insulin | | | | |
| 2-year | 8.00 (5.41–10.60) | 7.86 (6.97–8.75) | 5.34 (3.51–7.17) | 0.091 |
| 10-year | 8.95 (6.86–11.04) | 9.98 (8.20–11.76) | 7.13 (2.10–2.17) | 0.403 |
| HOMA-IR | | | | |
| 2-year | 0.34 (0.21–0.47) | 0.33 (0.29–0.38) | 0.21 (0.13–0.28) | 0.084 |
| 10-year | 0.43 (0.32–0.53) | 0.48 (0.38–0.58) | 0.35 (0.15–0.55) | 0.436 |

weight loss occurred (7,9). Weight reduction occurs faster after GBP than after banding or VBG (4), and even though it is well established that postoperative signaling patterns specific for GBP do exist (19,36,37), a negative energy balance also exists soon after GBP surgery. Indeed, several recent studies indicate that, despite profound changes in gut hormone patterns, pure caloric restriction may cause the short-term metabolic benefits of GBP in obese patients (25,26,28). When comparing GBP to calorie restriction, postprandial glucose levels were improved to a similar extent after both treatments (25,28) and treatment with a very low-calorie diet was as efficient as GBP for improving β -cell function and insulin sensitivity after patients had lost the same amount of weight (26). In patients without type 2 diabetes, it was shown that the improvement in insulin sensitivity was determined by the amount of weight lost—not whether the patients had been treated with GBP or calorie restriction (29). Furthermore, another study of patients without type 2 diabetes showed that effects on insulin sensitivity and β -cell function were similar after GBP and banding after 20% weight loss, occurring after 16 and 22 weeks, respectively (27). Consequently, it is important to investigate whether long-term effects on risk factor changes are similar after GBP compared with restrictive procedures when adequate adjustments for degree of weight loss have been performed.

In the current analyses of 2- and 10-year data from the SOS study, we found that when weight change was adjusted for, GBP was not associated with larger long-term reductions in fasting glucose,

fasting insulin, or HOMA-IR than those seen after banding or VBG. This was the case both when analyzing the total cohort and when subgrouping individuals by baseline glucose status. If anything, the reductions in fasting glucose within a given weight change class tended to be of smaller magnitude after GBP. In the SOS study, we previously showed that long-term diabetes remission frequencies are similar in GBP, VBG, and banding groups and that short diabetes duration and high baseline glucose are predictors for both short- and long-term diabetes remission (15). In the current report, we extend our findings by showing that the association between weight change and change in risk factor is similar for the three surgery techniques. However, as shown in the Supplementary Data, the group of patients with impaired fasting glucose or type 2 diabetes is responsible for the major part of the metabolic risk factor changes, whereas changes in the normal fasting glucose group are more modest.

This study has limitations. First, we cannot draw the conclusion that early weight loss-independent effects on glucose and insulin levels after GBP surgery do not exist. In the acute postoperative situation, changes in incretins, insulin, and glucose are no doubt larger after GBP than after banding (7,9). Unfortunately, we are unable to analyze acute weight loss-independent changes in the SOS study, since the first biochemical observations were not collected until 2 years after surgery. Second, different mechanisms affect postprandial (as assessed by glucose tolerance) and fasting plasma glucose levels (38,39). Studies in patients with impaired glucose tolerance have shown that reduced second-phase insulin release and peripheral insulin

resistance affect plasma glucose levels. In contrast, patients with impaired fasting glucose suffer from impaired basal insulin secretion and preferential resistance of glucose production to suppression by insulin (38). However, glucose tolerance tests or clamp examinations were not undertaken within the SOS study, making it impossible to draw conclusions on the long-term postprandial effects. Hence, we are unable to analyze whether postprandial glucose changes corrected for weight change are influenced differently by the three surgical techniques. Only fasting measures of insulin and glucose were available, and we therefore used HOMA-IR to estimate insulin resistance. For better understanding of the mechanisms behind changes in insulin sensitivity for different surgical techniques, long-term clamp studies are needed. In the group with normal fasting glucose at baseline, we found that the association between change in insulin and change in weight differed between the surgical groups. The reasons for this are not clear; however, it is possible that the association between insulin and weight is not linear throughout the entire weight loss range. If this were the case, the association would also depend on the absolute magnitude of weight loss and may thereby be different for GBP, which on average results in greater weight loss than the other techniques. In addition, the low participation rate in physical and laboratory examinations at 10 years is a limitation. Finally, the SOS study is a large prospective, controlled intervention study with >2,000 participants in the surgical group. This gives us a unique opportunity to perform detailed analyses on the long-term effects of bariatric surgery. However, the majority (68% [$n = 1,369$]) of the surgical patients in the SOS study underwent VBG, an operation that is rarely performed today, whereas 13% ($n = 265$) of the patients underwent the, at present, most common surgical technique (i.e., GBP). Furthermore, 17% ($n = 376$) of the surgical group underwent banding. This technique is still widely used, but there has been a significant decline in banding rates during the past few years (40).

In conclusion, given the same degree of weight loss after bariatric surgery, there was no support for weight loss-independent benefits of GBP over restrictive procedures on fasting glucose and insulin levels or HOMA-IR over 2

and 10 years. Hence, even though weight loss-independent effects that differ between surgical procedures are important for short-term remission, our results suggest that degree of weight loss is more important for long-term reductions in fasting insulin and glucose than choice of bariatric surgery procedure.

Acknowledgments. The authors thank the staff members at the 480 primary health-care centers and 25 surgical departments in Sweden that participated in the study. Gerd Bergmark, Christina Torefall, and Lisbeth Eriksson at the Department of Molecular and Clinical Medicine, Sahlgrenska Academy, are acknowledged for invaluable administrative support.

Funding and Duality of Interest. This study was supported by grants from the Swedish Research Council (K2013-99X-22279-01 and K2013-54X-11285-19), the Swedish Foundation for Strategic Research to Sahlgrenska Centre for Cardiovascular and Metabolic Research, the Swedish federal government under the LUA/ALF agreement concerning research and education of doctors, The Swedish Diabetes Foundation, F. Hoffmann-La Roche, Cederroths, AstraZeneca, Sanofi-Aventis, Ethicon, and Johnson & Johnson. K.S. is supported by a grant from the Swedish Agency for Innovation Systems. L.M.S.C. has served as a consultant for AstraZeneca and has received lecture fees from Johnson & Johnson. K.S. holds stock in Pfizer. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. K.S., E.S., and M.P. wrote the first version of the manuscript. K.S., L.M.S.C., and M.P. finalized the report. M.P. had principal responsibility for the statistical analyses of the data. All the authors participated in the interpretation of results and have seen, commented on, and approved the final report. L.M.S.C. and M.P. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of these data were presented in abstract form at the 15th International and 14th European Congress of Endocrinology, Florence, Italy, 5–9 May 2012.

References

1. *Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF Consultation.* Geneva, World Health Org., 2006
2. American Diabetes Association. Standards of medical care in diabetes—2013. *Diabetes Care* 2013;36(Suppl. 1):S11–S66
3. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. *Hepatol Res* 2013;43:51–64
4. Sjöström L, Lindroos AK, Peltonen M, et al.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 2004;351:2683–2693
5. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA* 2004;292:1724–1737
6. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med* 2009;122:248–256. e5
7. Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. *J Clin Endocrinol Metab* 2011;96:2227–2235
8. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. *Diabetes Metab* 2009;35:518–523
9. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. *Ann Surg* 2010;252:966–971
10. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. *Annu Rev Med* 2010;61:393–411
11. Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. *Endocrinology* 2009;150:2518–2525
12. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. *JAMA* 2008;299:316–323
13. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med* 2012;366:1567–1576
14. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. *N Engl J Med* 2012;366:1577–1585
15. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA* 2014;311:2297–2304
16. Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. *Diabetes Care* 2011;34:561–567
17. Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. *World J Surg* 2001;25:527–531
18. Hickey MS, Pories WJ, MacDonald KG Jr, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? *Ann Surg* 1998;227:637–643
19. Sweeney TE, Morton JM. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. *Best Pract Res Clin Gastroenterol* 2014;28:727–740
20. Curry TB, Roberts SK, Basu R, et al. Gastric bypass surgery is associated with near-normal insulin suppression of lipolysis in nondiabetic individuals. *Am J Physiol Endocrinol Metab* 2011;300:E746–E751
21. Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. *Diabetologia* 2012;55:1890–1901
22. Sjöholm K, Pajunen P, Jacobson P, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. *Diabetologia* 2015;58:1448–1453
23. Ballantyne GH, Wasieleski A, Saunders JK. The surgical treatment of type II diabetes mellitus: changes in HOMA Insulin resistance in the first year following laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB). *Obes Surg* 2009;19:1297–1303
24. Steven S, Carey PE, Small PK, Taylor R. Reversal of type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes. *Diabet Med* 2015;32:47–53
25. Lips MA, de Groot GH, van Klinken JB, et al. Calorie restriction is a major determinant of the short-term metabolic effects of gastric bypass surgery in obese type 2 diabetic patients. *Clin Endocrinol (Oxf)* 2014;80:834–842
26. Jackness C, Karmally W, Febres G, et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β -cell function in type 2 diabetic patients. *Diabetes* 2013;62:3027–3032
27. Bradley D, Conte C, Mittendorfer B, et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function. *J Clin Invest* 2012;122:4667–4674
28. Isbell JM, Tambori RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. *Diabetes Care* 2010;33:1438–1442
29. Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. *J Gastrointest Surg* 2010;14:15–23
30. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. *N Engl J Med* 2012;367:695–704
31. Sjöholm K, Anveden A, Peltonen M, et al. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish obese subjects (SOS) study. *Diabetes Care* 2013;36:1335–1340
32. Sjöström L, Gummesson A, Sjöström CD, et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. *Lancet Oncol* 2009;10:653–662
33. Sjöström L, Narbro K, Sjöström CD, et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 2007;357:741–752
34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. *JAMA* 2012;307:56–65
35. Sjöström L, Larsson B, Backman L, et al. Swedish obese subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. *Int J Obes Relat Metab Disord* 1992;16:465–479
36. Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric

- surgery: a 1-year prospective randomized pilot trial. *Obesity (Silver Spring)* 2013;21:E660–E668
37. Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borbély Y, Beglinger C. Effects of post-bariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. *Surg Obes Relat Dis* 2011;7:561–568
38. Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. *Diabetes Care* 2006;29:1909–1914
39. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. *Diabetes* 1999;48:2197–2203
40. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N. *Bariatric Surgery Worldwide* 2013. *Obes Surg* 2015;25:1822–1832